| Literature DB >> 15561317 |
A A Voors, D J van Veldhuisen.
Abstract
The role of angiotensin receptor blockers (ARBs) in patients with left ventricular dysfunction has changed after the VALIANT and CHARM trials. CHARM proved that candesartan is a good alternative for patients with chronic heart failure who cannot tolerate ACE-inhibitors. Moreover, VALIANT demonstrated non-inferiority of valsartan compared to captopril in patients after an acute myocardial infarction. The add-on effects of an ARB on top of an ACE-inhibitor are somewhat less pronounced, although a reduction in the number of hospitalizations for heart failure seems a consistent finding.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15561317 DOI： 10.1016/j.ijcard.2004.03.062
Source DB: PubMed Journal: Int J Cardiol ISSN： 0167-5273 Impact factor: 4.164